- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 14/605 - Glucagons
Détention brevets de la classe C07K 14/605
Brevets de cette classe: 1508
Historique des publications depuis 10 ans
|
97
|
113
|
90
|
134
|
138
|
136
|
166
|
131
|
141
|
9
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Novo Nordisk A/S | 2278 |
111 |
| Hanmi Pharm. Co., Ltd. | 552 |
80 |
| Zealand Pharma A/S | 241 |
78 |
| Eli Lilly and Company | 3720 |
69 |
| Sanofi | 3951 |
47 |
| Indiana University Research and Technology Corporation | 800 |
20 |
| Takeda Pharmaceutical Company Limited | 2943 |
18 |
| Sun Pharmaceutical Industries Limited | 759 |
18 |
| Merck Sharp & Dohme LLC | 3751 |
18 |
| Hanmi Science Co., Ltd. | 140 |
16 |
| MedImmune Limited | 622 |
16 |
| Intarcia Therapeutics, Inc. | 105 |
15 |
| President and Fellows of Harvard College | 5913 |
14 |
| The Scripps Research Institute | 1353 |
14 |
| Boehringer Ingelheim International GmbH | 4754 |
13 |
| Hybio Pharmaceutical Co., Ltd. | 120 |
13 |
| Duke University | 3011 |
12 |
| Bachem Holding AG | 35 |
12 |
| The Trustees of the University of Pennsylvania | 4260 |
11 |
| Ip2ipo Innovations Limited | 164 |
11 |
| Autres propriétaires | 902 |